GRFS Grifols SA
P/E
9.31
Forward P/E
5.81
Price/Sales
0.692
Beta
1.203
Div Yield
--
Market Cap
--
Company Analysis
Latest News
🟢 GRFS is trading 5.9% up today on Phase 3 trial milestone
GRFS is trading at $7.50 (+5.9%) after-hours following news that the company dosed the first patient in its SWIFT-SC Phase 3 trial for a self-administered...
Grifols Doses First Patient in Phase 3 Trial, Targeting Self-Administered Treatment
Grifols dosed the first patient in its global SWIFT-SC Phase 3 clinical trial. This study evaluates a new subcutaneous formulation of Alpha1-Proteinase...
Grifols votes on 50% capital expansion, targeting US Nasdaq listing
Grifols SA convenes its Annual General Shareholders’ Meeting today, June 18, 2026. Shareholders will vote on key board resolutions during this second-call...